Li F, Ayaki T, Maki T, Sawamoto N, Takahashi R. NLRP3 Inflammasome-Related Proteins Are Upregulated in the Putamen of Patients With Multiple System Atrophy. J Neuropathol Exp Neurol. 2018;77:1055-1065 pubmed publisher

Yang L, Mizuochi T, Shivakumar P, Mourya R, Luo Z, Gutta S, et al. Regulation of epithelial injury and bile duct obstruction by NLRP3, IL-1R1 in experimental biliary atresia. J Hepatol. 2018;69:1136-1144 pubmed publisher

Kosmidou C, Efstathiou N, Hoang M, Notomi S, Konstantinou E, Hirano M, et al. Issues with the Specificity of Immunological Reagents for NLRP3: Implications for Age-related Macular Degeneration. Sci Rep. 2018;8:461 pubmed publisher

Iacobini C, Menini S, Blasetti Fantauzzi C, Pesce C, Giaccari A, Salomone E, et al. FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice. Br J Pharmacol. 2017;: pubmed publisher

Li X, Thome S, Ma X, Amrute Nayak M, Finigan A, Kitt L, et al. MARK4 regulates NLRP3 positioning and inflammasome activation through a microtubule-dependent mechanism. Nat Commun. 2017;8:15986 pubmed publisher

Paramel Varghese G, Folkersen L, Strawbridge R, Halvorsen B, Yndestad A, Ranheim T, et al. NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis. J Am Heart Assoc. 2016;5: pubmed publisher

Hsieh H, Vignesh K, Deepe G, Choubey D, Shertzer H, Genter M. Mechanistic studies of the toxicity of zinc gluconate in the olfactory neuronal cell line Odora. Toxicol In Vitro. 2016;35:24-30 pubmed publisher

Panchanathan R, Liu H, Choubey D. Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation. Oncotarget. 2016;7:28183-94 pubmed publisher

Panchanathan R, Liu H, Leung Y, Ho S, Choubey D. Bisphenol A (BPA) stimulates the interferon signaling and activates the inflammasome activity in myeloid cells. Mol Cell Endocrinol. 2015;415:45-55 pubmed publisher